PRIA Pages is a quarterly publication highlighting PRIA Healthcare’s active involvement in key MedTech industry events, including the LSI Emerging MedTech Summit, Spine Summit, NANS Annual Meeting, and JP Morgan Healthcare Conference. It also features expert columns and workshops led by PRIA leaders, emphasizing trends in reimbursement, market access, and the support of emerging technologies through strategic partnerships like MedTech Innovator and Springboard Enterprises.
In the ever-evolving healthcare landscape, device manufacturers often focus on the reimbursement strategies tied to private insurance and traditional Medicare. However, there’s an important area that many overlook: Medicaid Managed Care. This represents a growing portion of the U.S. healthcare system, which has grown rapidly to 90 million Americans with a range of healthcare needs. But why is it important for device manufacturers to focus on not just Traditional but also Medicaid Managed Care? The answer lies in fee schedules.
Securing commercial insurance coverage for medical technology often hinges on one critical question: How much evidence is necessary to satisfy payer requirements? While “it depends” is a common, albeit frustrating, response, this article seeks to clarify this ambiguity and explain the factors driving the evidence requirements for the creation of medical policies.
For the fifth consecutive year, PRIA Healthcare is honored to sponsor LSI’s Emerging MedTech Summit – a premier gathering of visionaries dedicated to advancing healthcare innovation. LSI’s commitment to accelerate MedTech investment and commercialization resonates deeply with our own. At PRIA, we partner with innovators, investors, and industry leaders to bridge the gap between groundbreaking technology and real-world patient access. By navigating the complexities of market access, reimbursement, and commercialization, we help ensure that life-changing medical advancements reach the patients who need them most.
Innovating in today’s medical device industry is insanely hard. The majority of the MedTech industry consists of small companies – over 80% have fewer than 50 employees. The funding market has gotten significantly tougher in recent years. Most MedTech entrepreneurs are first timers, navigating unknowns with a long list of questions. Few go on to launch a second company, making veteran co-founders a rare breed.